STUB1 and breast carcinoma: Collectively, these results demonstrate that Bortezomib could indeed elevate ER stress in ErbB2-overexpressing breast cancer cells and that this effect was more pronounced in CHIP-low cells, supporting the rationale to test the effect of this inhibitor against control vs. CHIP KD tumor cells.